Compare · ABT vs SION
ABT vs SION
Side-by-side comparison of Abbott Laboratories (ABT) and Sionna Therapeutics Inc. (SION): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and SION operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $181.14B, about 981.9x SION ($184.5M).
- ABT has been more active in the news (13 items in the past 4 weeks vs 3 for SION).
- ABT has more recent analyst coverage (25 ratings vs 16 for SION).
- Company
- Abbott Laboratories
- Sionna Therapeutics Inc.
- Price
- $104.88+0.16%
- $3.91-3.69%
- Market cap
- $181.14B
- $184.5M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2025
- News (4w)
- 13
- 3
- Recent ratings
- 25
- 16
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Latest ABT
- Abbott introduces Ensure® Max Protein 3-in-1 Muscle Support, bringing the benefits of a supplement stack into one scoop
- Barclays initiated coverage on Abbott Labs with a new price target
- Abbott receives FDA approval for new CardioMEMS HF System capabilities that help patients engage in the care of their heart condition
- SEC Form 4 filed by Director Stratton John G
- SEC Form 4 filed by Director Gonzalez Patricia Paola
- SEC Form 4 filed by Director Conroy Kevin T
- SEC Form 4 filed by Director Ahuja Nita
- SEC Form 4 filed by Director Roman Michael F
- Abbott Labs upgraded by Rothschild & Co Redburn with a new price target
- Abbott hosts conference call for third-quarter earnings
Latest SION
- Sionna Therapeutics to Present Data at the 2026 North American Cystic Fibrosis Conference
- Director Ra Capital Management, L.P. sold $21,835,018 worth of shares (3,448,811 units at $6.33) (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13D/A filed by Sionna Therapeutics Inc.
- CFO and CBO Ridloff Elena was granted 94,537 shares, increasing direct ownership by 245% to 133,069 units (SEC Form 4)
- CMO and Head of R&D Mckee Charlotte was granted 100,000 shares, increasing direct ownership by 352% to 128,415 units (SEC Form 4)
- CLO and Head of Program Mgmt. Fitzpatrick Jennifer was granted 56,265 shares (SEC Form 4)
- President & CEO Cloonan Michael was granted 218,050 shares, increasing direct ownership by 40% to 765,393 units (SEC Form 4)
- SEC Form 144 filed by Sionna Therapeutics Inc.
- SEC Form 8-K filed by Sionna Therapeutics Inc.
- Sionna Therapeutics Announces Plans to Advance SION-451 + SION-2222 Dual Combination into Phase 2a Proof-of-Concept Trial